Abstract:Proper protein arginine methylation by protein arginine methyltransferase 1 (PRMT1) is critical for maintaining cellular health, while dysregulation is often associated with disease. How the activity of PRMT1 is regulated is therefore paramount, but is not clearly understood. Several studies have observed higher order oligomeric species of PRMT1, but it is unclear if these exist at physiological concentrations and there is confusion in the literature about how oligomerization affects activity. We therefore sought to determine which oligomeric species of PRMT1 are physiologically relevant, and quantitatively correlate activity with specific oligomer forms. Through quantitative western blotting, we determined that concentrations of PRMT1 available in a variety of human cell lines are in the sub‐micromolar to low micromolar range. Isothermal spectral shift binding data were modeled to a monomer/dimer/tetramer equilibrium with an EC50 for tetramer dissociation of ~20 nM. A combination of sedimentation velocity and Native polyacrylamide gel electrophoresis experiments directly confirmed that the major oligomeric species of PRMT1 at physiological concentrations would be dimers and tetramers. Surprisingly, the methyltransferase activity of a dimeric PRMT1 variant is similar to wild type, tetrameric PRMT1 with some purified substrates, but dimer and tetramer forms of PRMT1 show differences in catalytic efficiencies and substrate specificity for other substrates. Our results define an oligomerization paradigm for PRMT1, show that the biophysical characteristics of PRMT1 are poised to support a monomer/dimer/tetramer equilibrium in vivo, and suggest that the oligomeric state of PRMT1 could be used to regulate substrate specificity.

Substrate Specificity, Processivity, and Kinetic Mechanism of Protein Arginine Methyltransferase 5

Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5)

The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond

Arginine Methyltransferase 5 (PRMT5) Inhibitors with 3-(1H-benzo[d]imidazol- 2-Yl)anilines Core Identified by Virtual Screening and Biological Evaluation.

Theoretical insights into catalytic mechanism of protein arginine methyltransferase 1

Proteomics Profiling of Arginine Methylation Defines PRMT5 Substrate Specificity

Molecular basis for substrate recruitment to the PRMT5 methylosome

Medicinal chemistry strategies targeting PRMT5 for cancer therapy.

Small Molecule Inhibitors of Protein Arginine Methyltransferases

Protein arginine methylation: from enigmatic functions to therapeutic targeting

Discovery of Selective Protein Arginine Methyltransferase 5 Inhibitors and Biological Evaluations

Medicinal chemistry insights into PRMT5 inhibitors

Oligomerization of protein arginine methyltransferase 1 and its effect on methyltransferase activity and substrate specificity

Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders

Protein arginine methyltransferase 6 is a novel substrate of protein arginine methyltransferase 1

The Structure and Functions of PRMT5 in Human Diseases

Structure-Aided Design, Synthesis, and Biological Evaluation of Potent and Selective Non-Nucleoside Inhibitors Targeting Protein Arginine Methyltransferase 5.

Protein Arginine Methyltransferase 5: a Potential Cancer Therapeutic Target

Structure, Function, and Activity of Small Molecule and Peptide Inhibitors of Protein Arginine Methyltransferase 1

Versatility of PRMT5-induced methylation in growth control and development

Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies